Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
| Revenue (TTM) | $562.04M |
| Gross Profit (TTM) | $345.85M |
| EBITDA | $105.10M |
| Operating Margin | 9.13% |
| Return on Equity | 0.00% |
| Return on Assets | 3.84% |
| Revenue/Share (TTM) | $1.80 |
| Book Value | $-0.91 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -99.10% |
| Quarterly Revenue Growth (YoY) | -20.20% |
| Shares Outstanding | 0 |
| Float | $114.09M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Volatility is currently expanding